| 4.16 0.31 (8.05%) | 02-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.82 | 1-year : | 10.06 |
| Resists | First : | 5.84 | Second : | 8.61 |
| Pivot price | 3.98  |
|||
| Supports | First : | 1.36 | Second : | 1.13 |
| MAs | MA(5) : | 3.99  |
MA(20) : | 3.5 |
| MA(100) : | 4.39 |
MA(250) : | 6.71 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 35 |
D(3) : | 35.9 |
| RSI | RSI(14): 54.4 |
|||
| 52-week | High : | 17.68 | Low : | 1.36 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SXTP ] has closed below upper band by 48.1%. Bollinger Bands are 134.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.15 - 4.17 | 4.17 - 4.19 |
| Low: | 3.52 - 3.54 | 3.54 - 3.55 |
| Close: | 4.03 - 4.06 | 4.06 - 4.1 |
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
Wed, 04 Feb 2026
60 Degrees Pharmaceuticals (SXTP) Price Target Increased by 300.00% to 17.95 - Nasdaq
Mon, 02 Feb 2026
60 Degrees Pharmaceuticals stock falls after GoodRx partnership announcement - Investing.com
Mon, 02 Feb 2026
Malaria prevention pill ARAKODA gets GoodRx discounts at 70,000 pharmacies - stocktitan.net
Thu, 22 Jan 2026
60 Degrees Pharmaceuticals stock soars on new telehealth partnership - Investing.com
Thu, 22 Jan 2026
Here’s Why 60 Degrees Pharmaceuticals Stock (SXTP) Rocketed Today - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 2 (%) |
| Held by Institutions | 5.5 (%) |
| Shares Short | 62 (K) |
| Shares Short P.Month | 24 (K) |
| EPS | -2.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -5.02 |
| Profit Margin | 0 % |
| Operating Margin | -440 % |
| Return on Assets (ttm) | -70.1 % |
| Return on Equity (ttm) | -154.8 % |
| Qtrly Rev. Growth | 256.8 % |
| Gross Profit (p.s.) | 0.45 |
| Sales Per Share | 1.05 |
| EBITDA (p.s.) | -6.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -1.53 |
| PEG Ratio | 0 |
| Price to Book value | -0.82 |
| Price to Sales | 3.85 |
| Price to Cash Flow | -0.78 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|